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Introduction: Focal intrahepatic strictures are becoming more common owing to more prevalent and
accurate cross-sectional imaging. However, data relating to their management are lacking. The purpose
of the present review was to synthesize the current evidence regarding these lesions and to formulate a
strategy for diagnosis and management.
Methods: A literature search of relevant terms was performed using Medline. References of papers were
subsequently searched to obtain older literature.
Results: Focal intrahepatic strictures involve segmental hepatic ducts and/or left and right main hepatic
ducts during their intrahepatic course. Most patients are asymptomatic while the minority present with
vague abdominal pain or recurrent sepsis and only rarely with jaundice. Investigations used to distinguish
benign from malignant aetiologies include blood tests (CEA, Ca19.9), imaging studies [ultrasonography
(US), computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP) and
fluorodeoxyglucose-positron emission tomography (FDG-PET)], endoscopic modalities [endoscopic ret-
rograde cholangiopancreatography (ERCP)/endoscopic ultrasound (EUS)/cholangioscopy] and tissue
sampling (brush cytology/biopsy).
Conclusions: A focal intrahepatic stricture requires thorough investigation to exclude malignancy even
in patients with a history of biliary surgery, hepatolithiasis or parasitic infection. If during the investigative
process a diagnosis or suspicion of malignancy is demonstrated then surgical resection should be
performed. If all diagnostic modalities suggest a benign aetiology, then cholangioscopy with targeted
biopsies should be performed.
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Introduction
Biliary strictures most commonly involve the extrahepatic biliary
tree1 and usually present with clinical and biochemical evidence of
biliary obstruction.2 Focal intrahepatic strictures (FIHS) involve
the segmental intrahepatic ducts, are much rarer and are often
asymptomatic.3 They are often detected as incidental findings
after imaging performed for other reasons.4 The management of
these strictures requires a knowledge of their natural history and
appropriate diagnostic evaluation. The available literature regard-
ing management of these lesions is inconsistent and often contro-
versial.5 The purpose of this review was to synthesize the current
evidence regarding these lesions and to formulate a strategy for
diagnosis and management.
Methodology
A literature search of relevant terms was performed usingMedline
as detailed in Fig. 1. References of papers were subsequently
searched to obtain older literature.
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Incidence
FIHS are often asymptomatic and commonly found incidentally
with imaging or at autopsy3,6 making the incidence difficult to
assess. Approximately 10% of patients with no history of primary
sclerosing cholangitis (PSC) demonstrate ‘PSC-like’ strictures
at autopsy.6 Case reports3,7–13 and two small series collected over
decades, at a rate of approximately four patients per year,4,5 suggest
that the true incidence is much lower.
Clinical spectrum
Patients with FIHS fall into two clinical groups. The first, repre-
senting 30% of patients, is asymptomatic where the lesion is
identified incidentally.5 The second, representing the remaining
60% to 70%, present with vague symptoms which predominantly
include abdominal pain with occasional transient pyrexia and
jaundice.3,5 Abdominal pain occurring in almost half of these
patients5 is usually non-specific and tends to precede other symp-
toms.3 It is hypothesized that the pain is as a result of episodes
of cholangitis. Rigors and pyrexia occur in a minority (18%) of
patients whereas jaundice is less commonly associated with FIHS
(0% in the study by Seo and colleagues) than with other biliary
strictures.5
Natural history
The natural history of intrahepatic strictures depends on
accurate diagnostic evaluation which is often difficult and non-
confirmatory.4 There is no cohort of patients with FIHS who have
been followed over time to determine natural history. Some early
publications have suggested that recurrent cholangitis predomi-
nates3 whereas others suggest that biliary obstruction involving up
to 50% of liver parenchyma can be tolerated very well if there is no
associated infection and the remaining liver is unobstructed and
functional.14 A study examining liver transplant patients demon-
strated that in eight patients with unifocal intrahepatic strictures
all had near normal liver function and none developed biliary
symptoms nor required biliary intervention during a median
of 21-months follow-up.15 Although a specific patient cohort,
it demonstrates the possibly benign prognosis of such strictures
even in an immunocompromised patient group.
Differential diagnosis
Amongst multiple case reports, two series focus on FIHS. The first
is a retrospective surgical series involving 24 patients of whom one
half had benign pathology.4 The second is a prospective cholang-
ioscopic series that examined 17 patients who had FIHS and no
hepatolithiasis of whom 29% were found to be benign.5 Both
studies demonstrate that there are significant proportions of both
benign and malignant strictures.
Benign strictures can result from many pathological processes.
These include direct damage during biliary or liver surgery,
hepatic arterial ischaemia such as occurs during transarterial
chemoembolization (0.3%)16 or radiofrequency ablation (17%),17
chronic cholangitis (e.g. bacterial, eosinophilic such as IgG4
disease or parasitic) and hepatolithiasis.18 Diseases that are usually
multifocal such as primary sclerosing cholangitis (PSC) and Caro-
li’s disease may be localized and present with a FIHS.19–21 Benign
tumours may also present with localized intrahepatic dilatation
and an intraluminal filling defect mimicking a FIHS.22 A history of
any of the above features may suggest, but is not conclusive, of a
Medline 1948−2011
[(Exp bile ducts, intrahepatic) or (intrahepatic.tw)] and [(exp
constriction, pathologic) or (stricture.tw)]
n = 653
Excluded
Diagnostic tests
(n = 48)
Management
strategies
(n = 6)
Intrahepatic stones, mass forming cholangiocarcinoma,
hilar strictures
Blood tests
LFTs(2), CA19.9/CEA
(3), AFP(3)
Imaging
Ultrasound(2),CT(5),
MRI/MRCP(2), FDG-
PET(4), cholangiography
(3)
Tissue sampling
Aspiration cytology(3),
brush cytology(3),
biopsy(2)
Endoscopy
EUS(5), IDUS(6),
cholangioscopy(8)
Figure 1 Search strategy for literature review
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benign aetiology. Almost one-third of patients with malignant
intrahepatic strictures have a previous history of biliary surgery4
and up to 50% of patients have coexistent hepatolithiasis.23
The most important malignant cause of FIHS is cholangiocar-
cinoma representing 50–53% of patients in the current series4,5
whereas HCC, SCC andmetastatic disease occur rarely.3,7–13 Of the
three pathological growth types of intrahepatic cholangiocarci-
noma – mass-forming, periductal infiltrating and intraductal
growth – only periductal infiltrating and to a lesser extent intra-
ductal growing tumours are relevant as they can produce a FIHS
without a mass.24 A list of potential aetiologies for FIHS are
detailed in Table 1.
Diagnostic tests
These can be categorized as shown in Table 2.
Blood tests
Liver function tests
Abnormalities of liver function tests (LFTs) in FIHS tend to be
milder compared with those that cause more distal obstruction.5
alkaline phosphatase (ALP) and gamma glutamyltransferase levels
are elevated in the majority (65%) of patients, whereas bilirubin
levels are rarely abnormal.3,5 Although statistically significant
differences between levels of ALP have been associated with
malignant vs. benign strictures (>200 U/l, P = 0.0364), their ability
to distinguish the two groups is limited by poor sensitivity and
specificity.
CA19.9/CEA
Ca19.9 has been investigated as a tumour marker to distinguish
between malignant and benign biliary strictures in both the pres-
ence and absence of PSC. Patients with malignant strictures tend
to have statistically higher Ca19.9 levels than those with benign
strictures.4 In the absence of PSC, a Ca19.9 level >100 U/ml had a
sensitivity of 53% and a specificity of 92% for predicting malig-
nancy.25 However, a negative result does not exclude cholangio-
carcinoma. In the presence of PSC, the sensitivity of the Ca19.9
level is higher (89%) whereas the specificity is similar (86%)
for detecting the presence of malignancy,26 neither of which are
altered by the addition of a CEA level.27 It is also important to note
that very high Ca19.9 levels may be caused by benign conditions28
particularly in the presence of active bacterial cholangitis.29 These
levels, however, return to normal quickly after resolution of the
infection.28
Imaging
Ultrasound
Ultrasound may be used to identify dilated intrahepatic ducts
(>2 mm)30 proximal to a stricture or vascular involvement. In
the absence of a mass, its ability to characterize the stricture is
limited.4,31,32 However, ultrasound may identify other relevant
features such as the presence of hepatolithiasis33 or cirrhosis.
Computed tomography
Computed tomography (CT) imaging offers further information
including the location of the stricture, the presence of an enhanc-
ing or thickened duct wall, lymph node enlargement, vascular
invasion and the degree of intrahepatic biliary dilatation. Certain
features have been found to be associated more commonly with
malignant strictures compared with benign biliary strictures.
These include enhanced wall thickening (5 mm),4,34 lymph node
enlargement (1 cm)4,34 and portal vein obliteration34 although
Table 1 Differential diagnoses for focal intrahepatic strictures
BENIGN
Post-operative Post-biliary surgery
Inflammatory Hepatolithiasis, PSC, IgG4 disease
Ischaemic Post TACE/hepatic arterial injury, RFA
Direct toxicity Hepatic arterial floxuridine
Congenital Biliary anomalies e.g. Caroli's disease
Benign tumour Papillary adenoma
Infective Chronic cholangitis
– Bacterial, TB, Parasites
AIDS cholangiopathy
Idiopathic
Malignant
Cholangiocarcinoma
HCC
SCC
Liver metastases
PSC, primary sclerosing cholangitis; RFA, radiofrequency ablation;
TACE, transarterial chemoembolization; SCC, squamous cell carcinoma;
HCC, hepatocellular carcinoma.
Table 2 Diagnostic modalities for focal intrahepatic strictures
Blood tests Imaging Endoscopy Tissue sampling
LFTs Ca19.9/CEA Abdominal US EUS Aspiration
CT Intraductal US Brush cytology
MRI/MRCP Cholangioscopy Biopsy
PET
Cholangiography
US, ultrasonography; CT, computed tomography; MRI/MRCP, magnetic resonance imaging/magnetic resonance cholangiopancreatography;
PET, positron emission tomography; EUS, endoscopic ultrasound; LFTs, liver function tests.
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this has also been demonstrated with benign pathology.35 CT
imaging is unable to differentiate between malignant and benign
FIHS in the majority of patients.
Magnetic resonance imaging/magnetic resonance
cholangiopancreatography
Magnetic resonance imaging/magnetic resonance cholangiopan-
creatography (MRI/MRCP) detects the presence of a stricture
with a sensitivity of 93.5% and a specificity of 94.4%.36 It can also
assess for vascular involvement. However, there is no study that
has assessed its ability to distinguish benign frommalignant intra-
hepatic strictures. MRI has been shown to accurately distinguish
between 60–80% of hilar strictures.37–48 The degree to which this
can be extrapolated to FIHS is unclear (Fig. 2).
Fluorodeoxyglucose-positron emission tomography
There is limited information regarding positron emission tomog-
raphy (PET) scanning in the context of intrahepatic strictures.
Wakabayashi23 demonstrated in a small subset of patients (n = 5)
with intrahepatic strictures that PET has a sensitivity of 100% and
a specificity of 100% for distinguishing benign from malignant
disease. Nishiyama and colleagues assessed the accuracy of PET
scanning at identifying infiltrative cholangiocarcinoma (i.e. stric-
ture with no mass).49 They found that PET had a sensitivity of
75%.49 Apart from size of the lesions, the low sensitivity may also
relate to the degree of associated fibrosis49; however, little can be
concluded from such a small study group.
Cholangiography
Cholangiography of the biliary tree may be performed percuta-
neously or endoscopically if MRCP proves non-contributory.
Endoscopic retrograde cholangiopancreatography (ERCP) is
usually attempted before percutaneous cholangiography. EUS-
guided cholangiography has been attempted as an alternative to
percutaneous transhepatic cholangiography (PTC) facilitating
rendezvous procedures with retrograde or antegrade drainage.50
Cholangiographic features of intrahepatic strictures include
interruption of contrast medium, bile duct separation, tapering,
shouldering, mucosal irregularity, a filling defect and/or the
absence of opacification of the draining biliary tree segment.4 An
intrahepatic stricture can be more difficult to identify than an
extrahepatic stricture because it is either obscured by overlying
opacified ducts or it is not filled with contrast.51,52 Such a localized
stenosis that prevents proximal filling initially may be overcome
with higher injection pressure.
Distinguishing malignant from benign strictures is difficult and
controversial. Some authors suggest benign biliary strictures are
characteristically short and ring-like whereas malignant strictures
are generally long and irregular.3 Other authors suggest that only
an abrupt cut-off and bile duct separation are the statistically
significant distinguishing features.4 These appearances may be
confusing in the context of inflammation.52 Cholangiography
also fails to accurately assess the length and depth of bile duct
cancers.53,54
Endoscopy
Endoscopic ultrasound
Endoscopic ultrasound (EUS)-guided cholangiography can facili-
tate both diagnostic and therapeutic intervention when ERCP has
failed which occurs in up to 10% of patients.50,55–58 The proximity
between the stomach, duodenum and the biliary tree allows linear
array EUS access to this system59 in up to 91% of patients.50 There
are no data on sensitivity or specificity for intrahepatic strictures.
Intraductal ultrasound
In contrast to EUS, intraductal ultrasound (IDUS) is often better
able to image the proximal biliary system and surrounding struc-
tures.60,61 IDUS can be used to detect the extent and longitudinal
spread of bile duct carcinomas directing resection margins.54,61–64
Sensitivity of IDUS in non-PSC patients for distinguishing malig-
nant from benign strictures was 97% with a specificity of 89%.65
The above studies examined predominantly hilar strictures;
however, there are no specific data for intrahepatic strictures.
Cholangioscopy
Cholangioscopy provides good visualization of intrahepatic duct
lesions allowing distinction of benign from malignant pathology,
early detection of small and multiple foci along with the ability to
perform specific targeting of biopsies.66–71 It also allows for an
accurate assessment of proximal and distal cancer extension70,72 as
the superficial pattern of tumour spread may be more extensive
than suggested by the stricture itself.2
Cholangioscopy can be performed endoscopically67–69 or
percutaneously5,63,73–75 after a transhepatic tract has been dilated
Figure 2 Magnetic resonance cholangiopancreatography (MRCP) of
a focal intrahepatic stricture (FISH)
428 HPB
HPB 2012, 14, 425–434 © 2012 International Hepato-Pancreato-Biliary Association
to facilitate passage of the cholangioscope. The sensitivity of
percutaneous cholangioscopy for identifying malignant disease
ranges from 76% to 82%.63,74,75 Procedure-related morbidity
includes cholangitis (11.7%) and haemobilia (5.8%).5 Endo-
scopic cholangioscopy has also been investigated by several
groups.67–70 Disadvantages include difficulty negotiating intrahe-
patic strictures from the ampulla given their proximal location
while proximal cancer extension is also only possible to assess if
the miniscope is able to traverse the stricture.70 The equipment
required is fragile and easy to damage. It also may not be
possible in any patient whose ampulla is difficult to access
(e.g. Roux-en-Y reconstructions) although access with a double
balloon enteroscope is described.76 However, endoscopic cholan-
gioscopy is less invasive and does not carry the theoretical risk of
tumour seeding that potentially occurs in percutaneous cholan-
gioscopy.70 It also avoids the formation of a permanent biliary
fistula77 when a PTC drains an obstructed segment from above.
Potential complications of endoscopic drainage include cholan-
gitis as a result of contamination of a partially drained system –
mandating prophylactic antibiotics70 – and the standards risks of
endoscopy.
Several authors have examined the cholangioscopic features
that distinguish benign from malignant disease. Malignant stric-
tures such as papillary adenocarcinoma were associated with mul-
tiple polypoid mucosal projections whereas adenocarcinoma
was associated with irregular ductal mucosal changes with stric-
turing.5 Hepatocellular carcinoma (HCC) causing stricturing
appeared as a ‘chicken-fat’ like yellowish intraductal mass with
thrombi and the lesions tended to bleed on contact.5 Bile duct
adenomas appear as an intraductal polypoid mass.5 Tsuyuguchi’s
group combined several diagnostic criteria for malignancy from
previous percutaneous cholangioscopic studies2,78,79 including
irregularly dilated and tortuous vessels (‘tumour vessels’), contact
bleeding and an irregular surface. This gave a sensitivity of 100%,
a specificity of 86.8% and an accuracy of 93% for biliary stricture
diagnosis.80 Benign strictures by contrast demonstrate a smooth
stricture segment with no surface irregularities or abnormal
tumour vessels.5,81
Tissue sampling
There are three techniques available to acquire tissue for exami-
nation. The first is aspiration cytology where bile is aspirated via a
PTC catheter, ERCP catheter or via a nasobiliary drain yielding a
sensitivity of 55% and a specificity of 100%82 for malignancy. The
second technique is brush cytology whereby a metallic brush
is deployed across a stricture. The sensitivity for detection of
malignancy ranges from 33% to 58%.83–89 Poor sensitivity has
been attributed to poor sampling possibly owing to submucosal
tumour growth or extrinsic compression and techniques to
improve yield have included stricture dilation or repeated sam-
pling.90 The third technique is biopsy of the stricture which can be
facilitated during ERCP, PTC or EUS. Endoscopic transpapillary
biopsy of bile duct strictures has a sensitivity of 53–86% for cho-
langiocarcinoma.87,91 Fine needle aspiration/biopsy during EUS
has been more successful producing a sensitivity for biliary stric-
ture diagnosis of 43–86%.92–96 The sensitivity of EUS-FNA
for diagnosing malignancy within proximal biliary strictures
in patients who have had a negative ERCP tissue sampling is
25–83%.92,95,97
Several additional diagnostic modalities have been explored to
improve the low sensitivity of biliary cytology. These include flow
cytometry,98,99 digital imaging analysis,65 FISH, detection of K-ras
and p53 mutations and measurements of CA-19-9 and CEA99 in
bile fluid. The following data come from studies examining
common bile duct biliary strictures and not intrahepatic strictures
for which there are no trials.
The addition of flow cytometry to routine cytology increases
the diagnostic yield of brushings from biliary strictures from 42%
to 63% at the expense of a higher false-positive rate.98 Digital
imaging analysis (DIA) allows DNA content quantification,
assessment of chromatin distribution and nuclear morphology. It
is more sensitive at detecting malignancy in biliary strictures than
routine cytology (18% vs. 39% P = 0.014); however the overall
accuracy of DIA was no better than routine cytology.100 FISH
techniques have also demonstrated poor sensitivity compared
with routine cytology (15% vs. 34%)101 but FISH combined with
DIA allowed for a two- to five-fold increase in sensitivity when
compared with routine cytology.65 Analyses of K-ras codon 12
mutations in brush cytologies have yielded poor results for dis-
tinguishing malignant from benign biliary strictures because
K-ras mutations are variably associated with bile duct malignancy
and are commonly positive in benign pathology, particularly
pancreatic and PSC disease.102 Similarly, immunohistochemistry
analyses for p53 aberrations have yielded conflicting results103–105
and are presently not used in the diagnostic algorithm. Finally,
Ca19.9 and CEA levels in bile fluid demonstrated no diagnostic
benefit.99
While some studies show promising results, these tests have not
been widely adopted as a consequence of limited availability and a
marginal diagnostic advantage.
A summary of investigation features associated with malig-
nancy has been detailed in Table 3.
Management strategies
In fit patients, there are several management options available
for focal intrahepatic strictures. These include observation,
non-surgical treatment (such as endoscopic or percutaneous
dilatation/stenting) and surgical resection. The decision depends
on the risk of malignancy or the presence of symptoms.
Figure 3 outlines our proposed treatment algorithm.Note there
are two levels of investigation: ultrasound, CT and MRCP fol-
lowed by the more invasive EUS, ERCP and obtaining a tissue
diagnosis. The initial tests are used to identify a stricture and the
second-line investigations to characterize it.
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Given the high incidence of malignancy (50%–70%) found
in these strictures, if it is diagnosed or suspected at any point
throughout the investigative process, the stricture should be
resected allowing definitive diagnosis and management.
Malignancy is proven if biliary brushings or biopsy demon-
strate malignant cells whether obtained from ERCP, PTC or cho-
langioscopy. Findings suspicious for malignancy include CT/MRI
findings of a thickened biliary wall (>5 mm), lymph node enlarge-
ment (>1 cm), vessel occlusion and/or contrast enhancement of
the duct. They also would include cholangiographic findings of an
abrupt biliary cut-off or separation of the ducts. Suspicious find-
ings on cholangioscopy include irregular ductal mucosa, an intra-
ductal mass, contact bleeding or the presence of tumour vessels.
Some authors suggest that a formal hepatic resection should
be performed on the side of the stenosis because it fulfils the
principles of oncological surgery3; however, there are no data to
support anatomical vs. non-anatomical resection. Laparoscopic
resection for FIHS has been described previously.106
The approach is different for strictures that have no malignant
features. In the past, most authors have argued that they should
be resected owing to the inadequacy of the available diagnostic
tests.8,85,107–109 Our group believes that they warrant further inves-
tigation with cholangioscopy performed either endoscopically or
percutaneously if it is available. As noted above, the false-negative
rate for cholangioscopy is between 0–7%, lowered further if a
targeted biopsy is performed.4 If strictures appear benign on
pre-cholangioscopy investigations and a targeted biopsy does
not identify any malignancy then given the already low pre-test
probability of malignancy and high sensitivity, there is a very low
risk of missing malignancy in such patients after cholangioscopy.
If the patient is asymptomatic, observation would be appropriate
as there is no evidence that a benign stricture is pre-malignant
and it avoids the risks of intervention. These patients should be
followed-up and if a suspicious change is noted resection should
be the default therapy.
If the patient is symptomatic then some intervention is
required. While surgery is sometimes the only available option,
endoscopic and/or percutaneous options should be considered for
strictures that have no suspicious features on any investigations
including cholangioscopy. Endoscopic approaches are limited by
their ability to access and traverse intrahepatic strictures which lie
distant from the ampulla and stenting if required would need long
transampullary stents which are prone to dislodgement. Percuta-
neous transhepatic therapies are hampered by the need for exter-
nal drains or permanent stents which can cause futures problems
for patients with benign disease. Balloon dilatation remains a
viable option in both types of treatment. Biodegradable stents are
a potential option.110
Finally, the management of patients with a FIHS and associated
hepatolithiasis is controversial,111 has been previously explored by
previous authors and therefore has not been the focus of the
present reviww. Some authors argue for routine resection when a
biliary stricture associated with hepatolithiasis is isolated to a
single segment.111 Other authors suggest that endoscopic, includ-
ing cholangioscopic clearance and stricture dilatation is a less
morbid and anequally effective strategy in such patients.112–114 In
all, 10% of patients with hepatolithiasis have associated cholang-
iocarcinoma115; however, up to 50% of patients with malignant
biliary strictures have coexistent hepatolithiasis.23 Given the risk of
malignancy and the inaccuracy of diagnostic tests, we believe that
patients should undergo cholangioscopy at a minimum unless
resection is performed as the primary treatment modality.
The above algorithm contradicts the opinion of some previous
authors3 which predates both cholangioscopy and endoluminal
therapies. However, it does serve as a safe and comprehensive
pathway that reflects the currently published literature devoted to
this rare condition.
Conclusions
A focal intrahepatic stricture requires thorough investigation
to exclude malignancy even in patients with a history of biliary
surgery, hepatolithiasis or parasitic infection. If during the
investigative process a diagnosis or suspicion of malignancy is
demonstrated then surgical resection should be performed. If all
Table 3 Features on pre-operative investigations associated with
malignancy
Investigation Features associated with malignancy
LFTs
ALP >200 U/L
Tumour markers
Ca19.9 ↑Ca19.9
Imaging
Ultrasound Vascular involvement
CT Enhancing/thickened wall
Lymph node enlargement
Vascular invasion including PV involvement
MRI/MRCP Vascular involvement
Cholangiography Abrupt cut-off
Bile duct separation
Bile duct tapering/shouldering
Mucosal irregularity
Endoscopy
Cholangioscopy Polypoid mucosal projections
Irregular ductal mucosal changes
Yellow intraductal mass
Tumour vessels
Contact bleeding
Irregular surface
Tissue sampling Malignant cells
ALS, alkaline phosphatise; MRI/MRCP, magnetic resonance imaging/
magnetic resonance cholangiopancreatography; PV, portal vein; LFTs,
liver function tests.
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diagnostic modalities suggest a benign aetiology, then cholangios-
copy with targeted biopsies should be performed if it is available.
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